



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 6: C07D 413/10, A61K 31/42, 31/50	A1	(11) International Publication Number: WO 97/27188
		(43) International Publication Date: 31 July 1997 (31.07.97)

(21) International Application Number: PCT/GB97/00169	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 21 January 1997 (21.01.97)	
(30) Priority Data: 9601666.2 27 January 1996 (27.01.96) GB	
(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).	
(72) Inventor; and	Published
(75) Inventor/Applicant (for US only): BETTS, Michael, John [GB/GB]; Zeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).	With international search report.
(74) Agent: DENERLEY, Paul; Millington; Zeneca Pharmaceuticals, Intellectual Property Group, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).	

(54) Title: PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

(57) Abstract

The invention concerns a compound of formula (I) wherein: R¹ is of the formula -NHC(=O)(1-4C)alkyl, -NHS(O)_n(1-4C)alkyl wherein n is 0, 1 or 2 or R¹ is hydroxy; R² and R³ are independently hydrogen or fluoro; R⁴ is hydrogen, methyl, ethyl or oxo; R⁵ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or of the formula R⁶(CH₂)_m- wherein either m is 1-4 and R⁶ is, for example, trifluoromethyl, difluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkyl S(O)_p, wherein p is 0, 1 or 2, (1-6C)alkanoyloxy, di-(N-(1-4C)alkyl)amino, N-((1-4C)alkyl)(1-4C)alkanoylamino, cyano, carboxy, (1-4C)alkoxycarbonyl, carbamoyl, di-(N-(1-4C)alkyl)carbamoyl, N-((1-4C)alkyl)(1-4C)alkanesulphonamido, N¹-((1-4C)alkyl)-di-(N³-(1-4C)alkyl)ureido, or of the formula -OC(=O)NR⁷(R⁸) or -N(R⁹)SO₂NR⁷(R⁸) wherein R⁷ and R⁸ are independently hydrogen or (1-4C)alkyl and R⁹ is (1-4C)alkyl; or m is 2-4 and R⁶ is, for example, hydroxy, (1-4C)alkanoylamino, amino, (1-4C)alkylamino, (1-4C)alkanesulphonamido, ureido, di-(N³-(1-4C)alkyl)ureido or of the formula -NHSO₂NR⁷(R⁸); and pharmaceutically-acceptable salts thereof; processes for their preparation; pharmaceutical compositions containing them and their use as antibacterial agents.



BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PIPERAZINONEPHENYLOXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS

The present invention relates to antibiotic compounds, and in particular to antibiotic compounds containing both piperazinone and oxazolidinone rings. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.

The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded primarily as effective against Gram-positive pathogens because of their particularly good activity against such pathogens.


Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin-resistant staphylococcus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiply resistant Enterococcus faecium.

The major clinically effective antibiotic for treatment of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with nephrotoxicity and ototoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens.

The present inventors have discovered a class of antibiotic compounds containing an oxazolidinone ring which has useful activity against Gram-positive pathogens including MRSA and MRCNS and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used β -lactams.

We have now discovered a narrow range of compounds that is not suggested by the art and which has good activity against a broad range of Gram-positive pathogens including organisms known to be resistant to most commonly used antibiotics. In comparison with compounds described in the art (for example Walter A. Gregory et al in 5 J.Med.Chem. 1990, 33, 2569-2578 and Chung-Ho Park et al in J.Med.Chem. 1992, 35, 1156-1165) the compounds also possess a favourable toxicological profile.

Accordingly, the present invention provides a compound of the formula (I):



10

wherein:

R¹ is of the formula -NHC(=O)(1-4C)alkyl, -NHS(O)_n(1-4C)alkyl wherein n is 0, 1 or 2 or R¹ is hydroxy;

R² and R³ are independently hydrogen or fluoro;

15 R⁴ is hydrogen, methyl, ethyl or oxo;

R⁵ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or of the formula R⁶(CH₂)_m wherein either m is 1-4 and R⁶ is trifluoromethyl, difluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkyl S(O)_p- wherein p is 0, 1 or 2, (1-6C)alkanoyloxy, di-(N-(1-4C)alkyl)amino, N-((1-4C)alkyl)(1-4C)alkanoylamino, cyano, carboxy,


20 (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, di-(N-(1-4C)alkyl)carbamoyl, N-((1-4C)alkyl)(1-4C)alkanesulphonamido, N¹-((1-4C)alkyl)ureido, N¹-((1-4C)alkyl)-N³-((1-4C)alkyl)ureido, N¹-((1-4C)alkyl)-di-(N³-(1-4C)alkyl)ureido, or of the formula -OC(=O)NR⁷(R⁸) wherein R⁷ and R⁸ are independently hydrogen or (1-4C)alkyl or of the formula -N(R⁹)SO₂NR⁷(R⁸) wherein R⁷ and R⁸ are as hereinabove defined and R⁹ is (1-4C)alkyl;

25 or m is 2-4 and R⁶ is hydroxy, (1-4C)alkanoylamino, amino, (1-4C)alkylamino, (1-4C)alkanesulphonamido, ureido, N³-((1-4C)alkyl)ureido, di-(N³-(1-4C)alkyl)ureido or of the formula -NHSO₂NR⁷(R⁸) wherein R⁷ and R⁸ are as hereinabove defined; and pharmaceutically-acceptable salts thereof.

In this specification the generic term "alkyl" includes straight chained and branched structures, for example (1-6C)alkyl includes propyl, isopropyl and tert-butyl. However, references to individual alkyl groups such as "propyl" are specific for the straight-chain version only, and references to individual branched-chain alkyl groups such as 5 "isopropyl" are specific for branched-chain versions only. An analogous convention applies to other generic terms.

Examples of (1-4C)alkyl and (1-6C)alkyl include methyl, ethyl, propyl, isopropyl and tert-butyl; examples of N-(1-4C)alkylcarbamoyl include methylcarbamoyl and ethylcarbamoyl; examples of di(N-(1-4C)alkyl)carbamoyl include di(methyl)carbamoyl and 10 di(ethyl)carbamoyl; examples of (1-6C)alkylS(O)_p- include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, methylsulphonyl and ethylsulphonyl; examples of (2-6C)alkenyl include allyl and vinyl; examples of (2-6C)alkynyl include ethynyl and 2-propynyl; examples of (1-4C)alkoxy include methoxy, ethoxy and propoxy; examples of (1-6C)alkanoylamino include acetamido and propionylamino; examples of N-(1-4C)alkyl)(1-4C)alkanoylamino include N-methylacetamido, N-methylpropionylamino and N-ethylacetamido; examples of (1-6C)alkanesulphonamido include methanesulphonamido and ethanesulphonamido; examples of N-(1-4C)alkyl)-(1-4C)alkanesulphonamido include 15 N-(methyl)-methanesulphonamido, N-(methyl)ethanesulphonamido and N-(ethyl)ethanesulphonamido; examples of (1-4C)alkanoyloxy include acetoxy and 20 propionyloxy; examples of N-(1-4C)alkylamino include methylamino and ethylamino; examples of di-(N-(1-4C)alkyl)amino include di-N-methylamino, di-(N-ethyl)amino and N-ethyl-N-methylamino; examples of (1-4C)alkoxycarbonyl include methoxycarbonyl and ethoxycarbonyl; examples of N¹-(1-4C)alkyl)ureido include N¹-methylureido and 25 N¹-ethylureido; examples of N¹-(1-4C)alkyl)-N³-(1-4C)alkyl)ureido include N¹-methyl-N³-methylureido, N¹-ethyl-N³-methylureido and N¹-ethyl-N³-ethylureido; examples of N³-(1-4C)alkyl)ureido include N³-methylureido, and N³-ethylureido; and examples of 30 di-(N³-(1-4C)alkyl)ureido include di-(N³-methyl)ureido, N³-ethyl-N³-methylureido and di-(N³-ethyl)ureido.

The compounds of the present invention have a chiral centre at the C5-position. The pharmaceutically active enantiomer is of the formula (IA):



The present invention includes the pure enantiomer or diastereoisomer depicted above and mixtures of the 5(R) and 5(S) enantiomers or diastereoisomers, for example a racemic mixture or equal mixtures of diastereoisomers. If a mixture of 5(R) and 5(S) is used, a larger amount (depending up on the ratio of the enantiomers or diastereoisomers) will be required to achieve the same effect as the same weight of the pharmaceutically active enantiomer.

Furthermore, some compounds of the formula (I) may have other chiral centres.

It is to be understood that certain compounds of the formula I can exist in solvated as well as unsolvated form such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess antibacterial activity.

Suitable pharmaceutically-acceptable salts include acid addition salts such as

hydrochloride, hydrobromide, citrate, maleate, methanesulfonate, fumarate and salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as sodium, an alkaline earth metal salt for example calcium or magnesium, an ammonium or tetra-(2-hydroxyethyl)ammonium salt, an organic amide salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-

dibenzylethylamine or amino acids for example lysine. There may be more than one cation or anion depending on the number of charged functions and the valency of the cations or anions. A preferred pharmaceutically-acceptable salt is the sodium salt.

However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred whether pharmaceutically-acceptable or not.

The compounds of the formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the formula (I). Examples of pro-drugs include in-vivo hydrolysable esters of a compound of the formula (I).

An in-vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically-acceptable esters for carboxy include (1-6C)alkoxymethyl esters, for example methoxymethyl; (1-6C)alkanoyloxymethyl esters, for example pivaloyloxymethyl; phthalidyl esters; (3-8C)cycloalkylcarbonyloxy-(1-6C)alkyl esters, for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters, for example 5-methyl-1,3-dioxolen-2-onylmethyl; and (1-6C)alkoxycarbonyloxyethyl esters, for example 1-methoxycarbonyloxyethyl; and may be formed at any carboxy group in the compounds of this invention.

An in-vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent alcohol. The term includes inorganic esters such as phosphate esters and α -acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group.

Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxymethoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.

Preferred compounds of the invention comprise a compound of the formula (I), or a pharmaceutically-acceptable salt thereof, wherein the substituents R¹ to R⁹ have the values disclosed hereinbefore or have any of the following values :

- 25 a) Preferably R¹ is of the formula -NHC(=O)(1-4C)alkyl.
- b) Most preferably R¹ is acetamido.
- c) In another aspect R¹ is hydroxy.
- d) Preferably one of R² and R³ is hydrogen and the other is fluoro.
- e) Preferably R⁴ is hydrogen, methyl or oxo.
- 30 f) More preferably R⁴ is hydrogen or oxo.
- g) Most preferably R⁴ is hydrogen.

- h) Preferably R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is trifluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.
- i) More preferably, R⁵ is methyl, ethyl, 2, 2, 2-trifluoroethyl, 2-methoxyethyl, methylthiomethyl, methoxycarbonylmethyl, carbamoylmethyl, di-(N-methyl)carbamoylmethyl, 2-hydroxyethyl or 2-(acetamido)ethyl.
- j) Most preferably R⁵ is 2-fluoroethyl.

10

Therefore, in another aspect of the invention preferred compounds of the invention comprise a compound of the formula (I) wherein :

- a) R¹ is of the formula -NHC(=O)(1-4C)alkyl;
 15 R² and R³ is hydrogen and the other is fluoro;
 R⁴ is hydrogen, methyl or oxo;
 R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is trifluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or
 20 di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.
- b) R¹ is of the formula -NHC(=O)(1-4C)alkyl;
 R² and R³ is hydrogen and the other is fluoro;
 R⁴ is hydrogen, methyl or oxo;
 25 R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is trifluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or
 di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.
- c) R¹ is acetamido;
 R² and R³ is hydrogen and the other is fluoro;
 R⁴ is hydrogen, methyl or oxo;

R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is trifluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.

5

d) R¹ is acetamido;

R² and R³ is hydrogen and the other is fluoro;

R⁴ is hydrogen, methyl or oxo;

R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is 10 trifluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.

e) R¹ is hydroxy;

15 R² and R³ is hydrogen and the other is fluoro;

R⁴ is hydrogen, methyl or oxo;

R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is 20 trifluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.

f) R¹ is hydroxy;

R² and R³ is hydrogen and the other is fluoro;

R⁴ is hydrogen, methyl or oxo;

25 R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is trifluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.

30 g) R¹ is acetamido;

R² and R³ is hydrogen and the other is fluoro;

R⁴ is hydrogen or oxo;

R^5 is (1-6C)alkyl or of the formula $R^6(CH_2)_m-$ wherein either m is 1 or 2 and R^6 is trifluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R^6 is hydroxy or (1-4C)alkanoylamino.

5

h) R^1 is acetamido;

R^2 and R^3 is hydrogen and the other is fluoro;

R^4 is hydrogen or oxo;

R^5 is (1-6C)alkyl or of the formula $R^6(CH_2)_m-$ wherein either m is 1 or 2 and R^6 is

10 trifluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R^6 is hydroxy or (1-4C)alkanoylamino.

i) R^1 is acetamido;

15 R^2 and R^3 is hydrogen and the other is fluoro;

R^4 is hydrogen;

R^5 is (1-6C)alkyl or of the formula $R^6(CH_2)_m-$ wherein either m is 1 or 2 and R^6 is trifluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or

20 di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R^6 is hydroxy or (1-4C)alkanoylamino.

j) R^1 is acetamido;

R^2 and R^3 is hydrogen and the other is fluoro;

R^4 is hydrogen;

25 R^5 is (1-6C)alkyl or of the formula $R^6(CH_2)_m-$ wherein either m is 1 or 2 and R^6 is trifluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2),

(1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or

di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R^6 is hydroxy or (1-4C)alkanoylamino.

30 k) R^1 is acetamido;

R^2 and R^3 is hydrogen and the other is fluoro;

R^4 is hydrogen;

R^5 is methyl, ethyl, 2, 2, 2-trifluoroethyl, 2-methoxyethyl, methylthiomethyl, methoxycarbonylmethyl, carbamoylmethyl, di-(*N*-methyl)carbamoylmethyl, 2-hydroxyethyl or 2-(acetamido)ethyl.

5 1) R^1 is acetamido;

R^2 and R^3 is hydrogen and the other is fluoro;

R^4 is hydrogen;

R^5 is methyl, ethyl, 2, 2, 2-trifluoroethyl, 2-fluoroethyl, 2-methoxyethyl, methylthiomethyl, methoxycarbonylmethyl, carbamoylmethyl, di-(*N*-methyl)carbamoylmethyl, 2-hydroxyethyl or 10 2-(acetamido)ethyl.

Particular compounds of the present invention are:

N -((5*S*)-3-(3-fluoro-4-(4-methyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)-methyl)acetamide;

15 N -((5*S*)-3-(3-fluoro-4-(4-ethyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)-acetamide;

N -((5*S*)-3-(3-fluoro-4-(4-(2,2,2-trifluoroethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;

20 N -((5*S*)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;

N -((5*S*)-3-(3-fluoro-4-(4-(2-hydroxyethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;

25 N -((5*S*)-3-(3-fluoro-4-(4-(2-methoxyethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;

N -((5*S*)-3-(3-fluoro-4-(4-methoxycarbonylmethyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;

30 N -((5*S*)-3-(3-fluoro-4-(4-carbamoylmethyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;

N -((5*S*)-3-(3-fluoro-4-(4-*N,N*-dimethylcarbamoylmethyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;

N-((5S)-3-(3-fluoro-4-(4-(2-acetamidoethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide; or pharmaceutically-acceptable salts thereof.

Particular preferred compounds of the invention are :

N-((5S)-3-(3-fluoro-4-(4-methyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)-5-methylacetamide;

N-((5S)-3-(3-fluoro-4-(4-ethyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;


N-((5S)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide;

10 N-((5S)-3-(3-fluoro-4-(4-(2-methoxyethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide; or pharmaceutically-acceptable salts thereof.

An especially preferred compound of the invention is :

N-((5S)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide; or pharmaceutically-acceptable salts thereof.

15 In a further aspect the present invention provides a process for preparing a compound of the formula (I) or a pharmaceutically-acceptable salt thereof. The compounds of the formula (I) may be prepared by deprotecting a compound of the formula (II):



20

(II)

wherein R²-R⁴ are as hereinabove defined, R¹⁰ is R¹ or protected R¹ and R¹¹ is R⁵ or protected R⁵, and thereafter, if necessary, forming a pharmaceutically-acceptable salt.

25 Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Specific examples of protecting groups are given below for the sake of convenience, in which "lower" signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.

A carboxy protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).

Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (eg isopropyl, *tert*-butyl); lower alkoxy lower alkyl groups (eg methoxymethyl, ethoxymethyl, isobutoxymethyl; lower aliphatic acyloxy lower alkyl groups, (eg acetoxyethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxycarbonyloxy lower alkyl groups (eg 1-methoxycarbonyloxyethyl, 15 1-ethoxycarbonyloxyethyl); aryl lower alkyl groups (eg *p*-methoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (eg trimethylsilyl and *tert*-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups (eg trimethylsilylethyl); and (2-6C)alkenyl groups (eg allyl and vinylthethyl).

Methods particularly appropriate for the removal of carboxyl protecting groups 20 include for example acid-, metal- or enzymically-catalysed hydrolysis.

Examples of hydroxy protecting groups include lower alkenyl groups (eg allyl); lower alkanoyl groups (eg acetyl); lower alkoxycarbonyl groups (eg *tert*-butoxycarbonyl); lower alkenyloxycarbonyl groups (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, *o*-nitrobenzyloxycarbonyl, 25 *p*-nitrobenzyloxycarbonyl); tri lower alkyl/arylsilyl groups (eg trimethylsilyl, *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl); aryl lower alkyl groups (eg benzyl) groups; and triaryl lower alkyl groups (eg triphenylmethyl).

Examples of amino protecting groups include formyl, aralkyl groups (eg benzyl and substituted benzyl, eg *p*-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and 30 triphenylmethyl); di-*p*-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (eg *tert*-butoxycarbonyl); lower alkenyloxycarbonyl (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl,

o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl; trialkylsilyl (eg trimethylsilyl and *tert*-butyldimethylsilyl); alkylidene (eg methylidene); benzylidene and substituted benzylidene groups.

Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, metal- or enzymically-catalysed hydrolysis, for groups such as o-nitrobenzyloxycarbonyl, photolysis and for groups such as silyl groups, fluoride.

Examples of protecting groups for amide groups include aralkoxymethyl (eg. benzyloxymethyl and substituted benzyloxymethyl); alkoxyethyl (eg. methoxymethyl and trimethylsilylethoxymethyl); trialkyl/arylsilyl (eg. trimethylsilyl, *t*-butyldimethylsilyl, *tert*-butyldiphenylsilyl); tri alkyl/arylsilyloxyethyl (eg. *tert*-butyldimethylsilyloxyethyl, *tert*-butyldiphenylsilyloxyethyl); 4-alkoxyphenyl (eg. 4-methoxyphenyl); 2,4-di(alkoxy)phenyl (eg. 2,4-dimethoxyphenyl); 4-alkoxybenzyl (eg. 4-methoxybenzyl); 2,4-di(alkoxy)benzyl (eg. 2,4-di(methoxy)benzyl); and alk-1-enyl (eg. allyl, but-1-enyl and substituted vinyl eg. 2-phenylvinyl).

Aralkoxymethyl groups may be introduced onto the amide group by reacting the latter group with the appropriate aralkoxymethyl chloride, and removed by catalytic hydrogenation. Alkoxyethyl, tri alkyl/arylsilyl and tri alkyl/silyl groups may be introduced by reacting the amide with the appropriate chloride and removing with acid, or in the case of the silyl containing groups fluoride ions. The alkoxyphenyl and alkoxybenzyl groups are conveniently introduced by arylation or alkylation with an appropriate halide and removed by oxidation with ceric ammonium nitrate. Finally alk-1-enyl groups may be introduced by reacting the amide with the appropriate aldehyde and removed with acid.


For further examples of protecting groups see one of the many general texts on the subject, for example, 'Protective Groups in Organic Synthesis' by Theodora Green (publisher: 25 John Wiley & Sons).

In another aspect of the present invention the compounds of the formulae (I) and (II) and pharmaceutically-acceptable salts thereof can be prepared :-


a) by modifying a substituent in, or introducing a substituent into, another compound of the formula (I);

b) when R¹ is of the formula - NHS(O)_n(1-4C)alkyl, wherein n is 1 or 2, by oxidising a compound of the formula (I) wherein n is 0 or, when n is 2 by oxidising a compound of the formula (I) wherein n is 1;

(c) when R¹ is of the formula -NHC(=O)(1-4C)alkyl or -NHS(O)_n(1-4C)alkyl, by reacting a compound of the formula (III) with a compound of the formula (IV):




(III)




(IV)

d) when R¹ is hydroxy, by reacting a compound of the formula (V) with a compound of the formula (VI):




(V)



(VI)

- e) when R¹ or R¹⁰ is of the formula -NHC(=O)(1-4C)alkyl, the reaction of a compound of the formula (I) or (II) wherein R¹ or R¹⁰ is hydroxy, with an amide of the formula (VII):



(VII)

wherein R²-R⁴, R¹⁰ and R¹¹ are as hereinabove defined,

R¹² is of the formula -C(=O)(1-4C)alkyl or -S(O)_n(1-4C)alkyl,

R¹³ is (1-6C)alkyl or benzyl, R¹⁴ is (1-6C)alkyl and L¹ is a leaving group;
and thereafter if necessary: i) removing any protecting groups;

5

ii) forming a pharmaceutically-acceptable salt.

Methods for converting substituents into other substituents are known in the art. For example an alkylthio group may be oxidised to an alkylsulphanyl or alkysulphonyl group, a cyano group reduced to an amino group, a nitro group reduced to an amino group, a hydroxy group alkylated to a methoxy group, or a bromo group converted to an alkylthio group.

Compounds of the formula (I) or (II) wherein R¹ or R¹⁰ is -NHS(O)_n(1-4C)alkyl can be prepared by oxidising a compound of the formula (I) or (II) with standard reagents known in the art for the oxidation of a thio group to a sulphanyl or sulphonyl group. For example, a thio group may be oxidised to a sulphanyl group with a peracid such as m-chloroperoxybenzoic acid 15 and oxidising agents such as potassium permanganate will convert a thio group to a sulphonyl group. Compounds of the formula (I) or (II) wherein R¹ or R¹⁰ is -NHS(1-4C)alkyl can be prepared by reacting compounds of the formula (III) with a reagent such as (1-4C)alkylSCl.


Standard reaction conditions for the acetylation of an amine group in a compound of the formula (III) or its conversion to a sulphonamido group are known in the art. For example, 20 the amino group can be acetylated to give an acetamido group using the Schotten-Baumann

procedure; reacting the compound of the formula (III) with acetic anhydride in aqueous sodium hydroxide and THF in a temperature range of 0° to 60°C, preferably between 0°C and ambient temperature. Preferably the acylation is carried out *in situ* following the catalytic hydrogenation of a compound of the formula (IIIA) (below), by performing the hydrogenation in the presence 5 of acetic anhydride.

A compound of the formula (III) could for example be converted to a compound of the formula (I) or (II) wherein R¹ or R¹⁰ is (1-4C)SO₂NH- by reacting the compound of the formula (III) with a sulphonyl chloride. For example, by reacting the compound of the formula (III) with mesyl chloride in a mild base such as pyridine.

10 Alternatively compounds of the formula (I) or (II) wherein R¹ or R¹⁰ is (1-4C)alkylSO₂NH- or (1-4C)alkylSONH- may be prepared by reacting a compound of the formula (III) with a compound of the formula (IV) wherein L¹ is a phthalimido group, or preferably L¹ is halo, for example chloro.


15 The compound of the formula (IV) wherein L¹ is phthalimido may be prepared by oxidising a compound of the formula (IVA):



(IVA)

with standard oxidising agents known for the conversion of a thio group to a sulphinyl or sulphonyl group. Compounds of the formula (IVA) can be prepared by reacting phthalimide 20 with an alkylthiohalide, preferably the alkylthiocloride ((1-4C)alkylSCl).


A compound of the formula (III) may be prepared by reducing a compound of the formula (IIIA):



5 wherein R²-R⁴ and R¹¹ are as hereinabove defined.

Suitable reducing agents include triethylamine/hydrogen sulphide, triphenylphosphine or phosphite ester, or hydrogen in the presence of a catalyst. More specifically a compound of the formula (IIIA) may be converted to a compound of the formula (III) by heating it in an aprotic solvent, such as 1,2-dimethoxyethane, in the presence of P(OMe)₃ and subsequently 10 heating in 6N aqueous hydrochloric acid, or reacting it with hydrogen in the presence of palladium on carbon in an aprotic solvent such as DMF or ethyl acetate. For further details on the reduction of azides to amines see USP 4,705,799. A compound of the formula (IIIA) may be reduced and converted to a compound of the formula (I) or (II) *in situ* using acetic anhydride in DMF.

15 A compound of the formula (IIIA) may be prepared by reacting a compound of the formula (IIIB):



20

(IIIB)

wherein R¹⁵ is mesyloxy or tosyloxy, with a source of azide. For example, by reacting (IIIB) with sodium azide in an inert solvent such as DMF in a temperature range of ambient to 100°C, normally in the region of 75°C - 85°C. A compound of the formula (IIIB) may be prepared by 25 converting the hydroxy group in a compound of the formula (I) or (II) wherein R¹ or R¹⁰ is hydroxy into a tosyloxy or mesyloxy group by standard methods known in the art. For example,


by reacting said hydroxy compound of the formula (I) or (II) with tosyl chloride or mesyl chloride in the presence of a mild base such as triethylamine.

Alternatively, a compound of the formula (III) may be prepared using similar processes to those used hereinabove and hereinafter for the preparation of compounds of the 5 formulae (I) and (II).

Compounds of the formulae (V) and (VI) are conveniently reacted together in the presence of a strong base such as butyl lithium, lithium hexamethyldisilazide, lithium tert-butoxide, or lithium diisopropylamide. The reaction is conveniently carried out in an inert solvent such as tetrahydrofuran (THF), dimethylformamide (DMF), N,N¹-dimethylpropyleneurea (DMPU) or N-methylpyrrolidone in a temperature range of -78°C to 10 -50°C for the deprotonation and cyclisation. Suitable values for R¹³ include ethyl and benzyl and suitable values for R¹⁴ include ethyl and n-propyl, preferably n-propyl.

A compound of the formula (V) is conveniently prepared by reacting a chloroformate of the formula (ClCOOR¹³) with a compound of the formula (VA):

15




(VA)

20 wherein R²-R⁴ and R¹¹ are as hereinabove defined. The reaction is conveniently carried out in the presence of an inorganic or organic base such as sodium bicarbonate or an amine base such as dimethylaniline, the former in a solvent such as acetone/water and the latter in an organic solvent such as THF, toluene, DMF or acetonitrile.

A compound of the formula (VA) may be prepared by reducing a compound of the 25 formula (VB):

- 18 -




(VB)

5 wherein R²-R⁴ and R¹¹ are as hereinabove defined.


Many reduction methods suitable for the reduction of a nitro to an amino group are known in the art, for example catalytic hydrogenation and metal reductions. Suitable catalysts in catalytic hydrogenation include Raney nickel, platinum metal and its oxide, rhodium, palladium-on-charcoal and Wilkinson's catalyst RhCl (Ph₃P)₃. Catalytic hydrogenation is conveniently carried out in the temperature range 0°C - 150°C, but preferably at ambient temperature at slightly above atmospheric pressure.

A compound of the formula (VB) is conveniently prepared by reacting together compounds of the formulae (VC) and (VD):



15

(VC)



20


(VD)

wherein R²-R⁴ and R¹¹ are as hereinabove defined and L² is a leaving group, preferably halo and in particular fluoro.

The reaction between compounds of the formulae (VC) and (VD) is carried out in the presence of an organic or inorganic base such as sodium bicarbonate, potassium carbonate or an amine base such as diisopropylethylamine, in an inert solvent such as acetonitrile, DMF, DMPU or N-methylpyrrolidone, in a temperature range of 50°C - 150°C.

Compounds of the formula (VD) may be prepared by introducing R¹¹ into a compound of the formula (VE):

10



(VE)

wherein R¹⁶ is a protecting group, and subsequently removing R¹⁶ (deprotecting). Preferably 15 R¹⁶ is *tert*-butoxycarbonyl.

For example, when R¹¹ is a substituted or unsubstituted alkyl group, the compound of the formula (VE) may be reacted with R¹¹-L³ wherein L³ is a leaving group, in particular tosylate or halo in the presence of a strong base. Suitable bases include sodium hydroxide, lithium diisopropylamide, butyllithium and potassium butoxide. The reaction is usually 20 performed in an inert solvent such as THF or DMF in a temperature range of 0°C - 100°C.

Alternatively, when R¹¹ is alkyl substituted by an electronegative group, R¹¹ may be introduced into the compound of the formula (VE) by reacting it with the related alkene. The compound of the formula (VD) wherein R¹¹ is 2-hydroxyethyl may be prepared by heating the compound of the formula (VE) with ethylene oxide in the temperature range of 25 40°C - 100°C.

It may be synthetically simpler to prepare some compounds of the formula (VD) by introducing a substituent onto the unsubstituted ring nitrogen in the compound of the formula (VE) which could subsequently be converted into the desired R¹¹. For example,

2-cyanoethyl could be introduced onto the ring nitrogen, and reduced to an amino group which itself could be alkylated to alkylamino.

The reaction of a compound of the formula (I) or (II) wherein R¹ or R¹⁰ is hydroxy with an amide of the formula (VII) is conveniently carried out in the presence of tri-n-5 butylphosphine and 1,1'-(azodicarbonyl)dipiperidine in an organic solvent such as THF, and in the temperature range 0° - 60°C, but preferably at ambient temperature. Details of analogous Mitsunobu reactions are contained in Tsunoda et al, Tet.Letts., 34, 1639, (1993). Amides of the formula (VII) may be prepared by standard procedures of organic chemistry which are within the ordinary skill of an organic chemist.

10 When an optically active form of a compound of the formula (I) is required, it may be obtained, by carrying out one of the above procedures using an optically active starting material or by resolution of a racemic form of the compound or intermediate using a standard procedure.

According to a further feature of the invention there is provided a compound of the formula (I), or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of 15 the human or animal body by therapy.

According to a further feature of the present invention there is provided a method for producing an antibacterial effect in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the present invention, or a pharmaceutically-acceptable salt thereof.

20 The invention also provides the use of a compound of the present invention, or a pharmaceutically-acceptable salt thereof, in the manufacture of a novel medicament for use in the production of an antibacterial effect in a warm blooded animal, such as man.

In order to use a compound of the formula (I) or a pharmaceutically-acceptable salt thereof for the therapeutic treatment of mammals including humans, in particular in treating 25 infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically-acceptable salt thereof and a pharmaceutically-acceptable carrier.

30 The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral administration. For these purposes the compounds of this invention may be

formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, eye drops, nasal drops and sterile injectable aqueous or oily solutions or suspensions.

- 5 In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered with, one or more known drugs selected from other clinically useful antibacterial agents (for example β -lactams or aminoglycosides). These may include penicillins, for example oxacillin or flucloxacillin and carbapenems, for example meropenem or imipenem, to broaden the therapeutic effectiveness.
- 10 Compounds of this invention may also contain or be co-administered with bactericidal/permeability-increasing protein (BPI) or efflux pump inhibitors to improve activity against Gram-negative bacteria and bacteria resistant to antimicrobial agents.
- 15 A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 100mg and 1g of the compound of this invention.

In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.

- Each patient may receive, for example, a daily intravenous, subcutaneous or intramuscular dose of 5 mgkg⁻¹ to 20 mgkg⁻¹ of the compound of this invention, the 20 composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.

25

Antibacterial Activity

The pharmaceutically-acceptable compounds of the present invention are useful antibacterial agents having a good spectrum of activity *in vitro* against standard Gram-positive organisms, which are used to screen for activity against pathogenic bacteria. Notably, the 30 pharmaceutically-acceptable compounds of the present invention show activity against enterococci, pneumococci and methicillin resistant strains of *S. aureus* and coagulase negative

staphylococci. The antibacterial spectrum and potency of a particular compound may be determined in a standard test system.

The antibacterial properties of the compounds of the invention may also be demonstrated *in vivo* in conventional tests. No overt toxicity or other untoward effects are observed when compounds of the formula I are so tested.

The following results were obtained on a standard *in vitro* test system. The activity is described in terms of the minimum inhibitory concentration (MIC) determined by the agar-dilution technique with an inoculum size of 10^4 CFU/spot.

Staphylococci were tested on agar, using an inoculum of 10^4 CFU/spot and an incubation temperature of 37°C for 24 hours - standard test conditions for the expression of methicillin resistance.

Streptococci and enterococci were tested on agar supplemented with 5% defibrinated horse blood, an inoculum of 10^4 CFU/spot and an incubation temperature of 37°C in an atmosphere of 5% carbon dioxide for 48 hours - blood is required for the growth of some of the test organisms.

<u>Organism</u>	<u>MIC (µg/ml)</u>	<u>Example 1</u>
-----------------	--------------------	------------------

20 **Staphylococcus aureus:**

Oxford	1
Novb. Res	2
MRQS	2
MRQR	4

25 **Coagulase Negative Staphylococci**

MS	0.5
MR	1

Streptococcus pyogenes

C203	1
------	---

30 **Enterococcus faecalis**

Bacillus subtilis	1
-------------------	---

Novb. Res = Novobiocin resistant

MRQS = methicillin resistant quinolone sensitive

MRQR = methicillin resistant quinolone resistant

MR = methicillin resistant

5

The invention is now illustrated but not limited by the following Examples in which unless otherwise stated :

- i) evaporation were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids by filtration;
- 10 (ii) operations were carried out at ambient temperature, that is in the range 18-26°C and in air unless otherwise stated, or unless the skilled person would otherwise work under an inert atmosphere;
- (iii) column chromatography (by the flash procedure) was performed on Merck Kieselgel silica (Art. 9385);
- 15 (iv) yields are given for illustration only and are not necessarily the maximum attainable;
- (v) the structures of the end-products of the formula I were confirmed by NMR and mass spectral techniques [proton-magnetic-resonance spectra were determined in D6-DMSO unless otherwise stated using a Varian Gemini 2000 spectrometer operating at a field strength of 300 MHz, or a Bruker AM250 spectrometer operating at a field strength of 250 MHz; chemical shifts are reported in parts per million downfield (δ scale), using tetramethylsilane as an internal standard when using CDCl_3 , but otherwise using an internal signal when using D6-DMSO; and peak multiplicities are shown thus: s, singlet; d, doublet; dd, doublet of doublets; ddd, doublet of double doublets; t, triplet; q, quartet; dq, doublet of quartets; m, multiplet; dm, doublet of multiplets; br, broad; fast-atom bombardment (FAB) mass spectral data were obtained using a Platform spectrometer (supplied by Micromass) run in electrospray and, where appropriate, either positive ion data or negative ion data were collected];
- (vi) intermediates were not generally fully characterised and purity was in general assessed by thin layer chromatographic, infra-red (IR), mass spectral (MS) or NMR analysis;
- 30 and

(vii) the following abbreviations have been used:

DMF	N,N-dimethylformamide;
THF	tetrahydrofuran;
TFA	trifluoroacetic acid;
DMSO	dimethylsulfoxide;
CDCl ₃	deuterated chloroform;
CI	chemical ionization;
DMPU	1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (N,N-dimethylpropylene urea).

Example 1

(5R)-5-Azidomethyl-3-(3-fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one (820mg) was dissolved in dry DMF (20 ml), and the solution purged with argon. Palladium (10% on carbon, 164mg) was added, and the mixture stirred at ambient temperature for 2 hours under hydrogen confined in a balloon. Pyridine (0.38 ml) and acetic anhydride (0.44 ml) were added, and the mixture stirred at ambient temperature for 16 hours. The mixture was evaporated to dryness, and chromatographed on silica using as eluant a gradient increasing in polarity from 0 to 5% methanol in dichloromethane. Relevant fractions were combined and evaporated to give N-(5S)-[3-(3-fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (350mg).

MS (Electrospray): 365 (MH⁺).

NMR (CDCl₃) δ: 2.02 (s, 3H); 3.03 (s, 3H); 3.41 (t, 2H); 3.46 (t, 2H); 3.55-3.72 (m, 2H); 3.76, 3.77 (s + dd, 2H + 1H); 4.06 (t, 1H); 4.76 (m, 1H); 6.17 (br t, 1H); 6.91 (t, 1H); 7.08 (dm, 1H); 7.48 (dd, 1H).

The (5R)-5-azidomethyl-3-(3-fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one used as starting material was obtained as follows :-

20

1-*tert*-Butoxycarbonyl-3-oxopiperazine (see Tetrahedron Lett. (1980), 21(32), 3019-20 for outline of synthesis, 5g) was dissolved in dry DMF (75 ml) and potassium *tert*-butoxide (3.08g) was added. The mixture was stirred at ambient temperature for 1 hour, then iodomethane (3.9g) was added, and stirring continued at the same temperature for 2.5 hours.

25 Solvent was evaporated, and the residue chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 100% ethyl acetate in iso-hexane. Relevant fractions were combined and evaporated to give 1-*tert*-butoxycarbonyl-4-methyl-3-oxopiperazine (3.92g).

30 MS (CI): 215 (MH⁺).

NMR (CDCl₃) δ: 1.48 (s, 9H); 3.01 (s, 3H); 3.35 (t, 2H); 3.66 (t, 2H); 4.08 (s, 2H).

1-*tert*-Butoxycarbonyl-4-methyl-3-oxopiperazine (3.87g) was dissolved in trifluoroacetic acid (80 ml), and the mixture stirred at ambient temperature for 2 hours. Solvent was evaporated to give 1-methyl-2-oxopiperazine as a trifluoroacetate salt, with some excess trifluoroacetic acid.

5 MS (CI): 114 (MH⁺).

10 NMR (CDCl₃) δ: 3.11 (s, 3H); 3.62 (t, 2H); 3.72 (t, 2H); 4.05 (s, 2H).

N,N-Diisopropylethylamine (11.5 ml) and 1-methyl-2-oxopiperazine (4.12g) were added to a solution of 3,4-difluoronitrobenzene (1.82 ml) in acetonitrile (100 ml), and the mixture heated to reflux for 16 hours. Solvent was evaporated, and the residue chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 100% ethyl acetate in iso-hexane. Relevant fractions were combined and evaporated to give 3-fluoro-4-(4-methyl-3-oxopiperazin-1-yl)nitrobenzene (3.37g).

15 MS (CI): 254 (MH⁺).

20 NMR (DMSO-D₆) δ: 3.06 (s, 3H); 3.53 (t, 2H); 3.67 (t, 2H); 3.97 (s, 2H); 6.90 (t, 1H); 7.95 (dd, 1H); 8.02 (m, 1H).

25 3-Fluoro-4-(4-methyl-3-oxopiperazin-1-yl)nitrobenzene (3.33g) was dissolved in a mixture of DMF (40 ml) and methanol (10 ml), and the solution flushed with argon. Ammonium formate (4.15g) was added, and the mixture cooled to 5° C. Palladium (10% on carbon, 104mg) was added, and the temperature allowed to rise to ambient as the mixture was stirred under argon for 2 hours. Solvents were evaporated to give an air sensitive product, 5-amino-2-(4-methyl-3-oxopiperazin-1-yl)fluorobenzene, which was used as such in the next stage.

30

MS (CI): 224 (MH⁺).

NMR (CDCl₃) δ: 3.02 (s, 3H); 3.27 (t, 2H); 3.42 (t, 2H); 3.69 (s, 2H); 4.13 (br s, 2H); 6.40 (m, 1H); 6.44 (dd, 1H); 6.77 (t, 1H).

5-Amino-2-(4-methyl-3-oxopiperazin-1-yl)fluorobenzene (2.94g) was dissolved in dry DMF (40 ml) under argon, and the solution cooled to -20°C. N,N-Dimethylaniline (2.1 ml) was added, followed by benzyl chloroformate (2.07 ml), and the mixture stirred for 10 minutes at -20°C. The temperature was allowed to rise to ambient over 16 hours. The mixture was diluted with ethyl acetate, and washed twice with water, and then brine. After drying (MgSO₄) and evaporation of solvent, the residue was chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 5% methanol in dichloromethane. Relevant fractions were combined and evaporated to give 5-benzyloxycarbonylamino-2-(4-methyl-3-oxopiperazin-1-yl)fluorobenzene (4.6g).

MS (CI): 358 (MH⁺).

15

NMR (CDCl₃) δ: 2.97 (s, 3H); 3.31 (t, 2H); 3.41 (t, 2H); 3.70 (s, 2H); 5.16 (s, 2H); 6.81 (t, 1H); 6.98 (m, 2H); 7.33 (m, 6H).

5-Benzylloxycarbonylamino-2-(4-methyl-3-oxopiperazin-1-yl)fluorobenzene (4.5g) was dissolved in dry THF (100 ml) under argon and the solution cooled to -78°C. A solution of n-butyllithium (8.67 ml, 1.6 M in hexane) was added to this whilst keeping the temperature below -60°C. The mixture was stirred for 5 minutes and (R)-glycidylbutyrate (1.86 ml) was added. Stirring was continued at -78°C for 30 minutes and the temperature then allowed to rise to ambient over 16 hours. The mixture was evaporated to dryness and then treated with dichloromethane. The mixture was filtered to give (5R)-3-(3-fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)-5-hydroxymethyloxazolidin-2-one (409mg). The residual organic solution was washed twice with water, and then brine. After drying (MgSO₄) and evaporation of solvent, the residue was chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 6% methanol in dichloromethane. Relevant fractions were combined and evaporated to give further (5R)-3-(3-fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)-5-hydroxymethyloxazolidin-2-one product (535mg).

MS (CI): 324 (MH⁺).

NMR (CDCl₃ + DMSO-D₆) δ: 2.99 (s, 3H); 3.38 (t, 2H); 3.48 (t, 2H); 3.67, 3.70 (m + s, 3H); 3.82 (m, 1H); 3.94 (dd, 1H); 4.03 (t, 1H); 4.69 (m, 1H); 5.09 (t, 1H); 6.95 (t, 1H); 7.14 (dd, 1H); 7.56 (dd, 1H).

(5R)-3-(3-Fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)-5-hydroxymethyloxazolidin-2-one (900mg) was dissolved in pyridine (20 ml), and cooled to 0°C. Triethylamine (0.5 ml) and methanesulfonyl chloride (0.24 ml) were added, and stirring continued at 5°C for 2 hours. Solvent was evaporated, and the residue chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 3% methanol in dichloromethane. Relevant fractions were combined and evaporated to give (5R)-3-(3-fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)-5-(methanesulfonyloxy)methyl)oxazolidin-2-one (990mg).

15 MS (Electrospray): 402 (MH⁺).

NMR (CDCl₃) δ: 3.04 (s, 3H); 3.11 (s, 3H); 3.42 (dt, 4H); 3.77 (s, 2H); 3.93 (dd, 1H); 4.13 (t, 1H); 4.48 (dq, 2H); 4.92 (m, 1H); 6.92 (t, 1H); 7.11 (dd, 1H); 7.50 (dd, 1H).

20 Sodium azide (924mg) was added to a solution of (5R)-3-(3-fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)-5-(methanesulfonyloxy)methyl)oxazolidin-2-one (950mg) in dry DMF (50 ml), and the mixture heated at 75°C for 2 hours. The mixture was diluted with ethyl acetate and washed with three portions of water. The aqueous layer was then back-extracted with two portions of ethyl acetate, and the combined organic extracts dried over 25 MgSO₄. Evaporation gave (5R)-5-azidomethyl-3-(3-fluoro-4-{4-methyl-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one product which was used without further purification.

MS (CI): 402 (MH⁺).

30 NMR (CDCl₃) δ: 3.03 (s, 3H); 3.42 (dm, 4H); 3.59 (dd, 1H); 3.71 (dd, 1H); 3.77 (s, 2H); 3.83 (dd, 1H); 4.06 (t, 1H); 4.80 (m, 1H); 6.91 (t, 1H); 7.12 (dm, 1H); 7.51 (dd, 1H).

Example 2.

(5R)-5-Azidomethyl-3-(3-fluoro-4-{4-ethyl-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one (750mg) was dissolved in a mixture of DMF (5 ml) and ethyl acetate (10 ml), and the solution purged with argon. Palladium (10% on carbon, 150mg) was added, followed by 5 acetic anhydride (0.4 ml) and the mixture stirred at ambient temperature under hydrogen confined in a balloon for 2 hours. The mixture was filtered through celite, evaporated to dryness, and chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 10% methanol in dichloromethane. Relevant fractions were combined and evaporated, and the residue purified by crystallisation from acetonitrile to give N-(5S)-[3-(3-fluoro-4-{4-ethyl-3-oxopiperazin-1-yl}phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (145mg).

MS (Electrospray): 379 (MH^+).

¹⁵ **NMR (DMSO-D₆) δ:** 1.06 (t, 3H); 1.83 (s, 3H); 3.25-3.45 (overlapping m, 8H); 3.59 (s, 2H); 3.70 (dd, 1H); 4.17 (t, 1H); 4.70 (m, 1H); 7.17 (t, 1H); 7.35 (dd, 1H); 7.51 (dd, 1H); 8.19 (br t, 1H).

The (5R)-5-azidomethyl-3-(3-fluoro-4-{4-ethyl-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one used as starting material was prepared as follows :-

1-*tert*-Butoxycarbonyl-3-oxopiperazine (7.5g) was dissolved in dry DMF (250 ml) and potassium *tert*-butoxide (8.4g) was added. The mixture was stirred at ambient temperature for 30 minutes, then iodoethane (3.3 ml) added, and stirring continued at the same 25 temperature for 24 hours. A further equal portion of iodoethane was added and stirring continued for 24 hours. Solvent was evaporated, and the residue partitioned between ethyl acetate and water. The organic layer was washed with water, evaporated, and purified by chromatography on silica, using as eluant a gradient increasing in polarity from 0 to 25% isopropanol in iso-hexane. Relevant fractions were combined and evaporated to give **1-*tert*-butoxycarbonyl-4-ethyl-3-oxopiperazine** (6.0g).

MS (CI): 229 (MH^+)

NMR (CDCl₃) δ: 1.16 (t, 3H); 1.47 (s, 9H); 3.34 (t, 2H); 3.46 (q, 2H); 3.64 (t, 2H); 4.06 (s, 2H).

5 1-*tert*-Butoxycarbonyl-4-ethyl-3-oxopiperazine (5.9g) was dissolved in dichloromethane (100 ml), cooled in an ice-bath, and trifluoroacetic acid (145 ml) added. The mixture was stirred at the same temperature for 2 hours. Solvent was evaporated to yield 1-ethyl-2-oxopiperazine

product as a salt with 3 moles of trifluoroacetic acid.

10

MS (CI): 129 (MH⁺).

NMR (DMSO-D₆ + CD₃CO₂H) δ: 1.09 (t, 3H); 3.41, 3.45 (q + t, 4H); 3.54 (t, 2H); 3.76 (s, 2H).

15

1-Ethyl-2-oxopiperazine (3TFA salt, 10.5 g) was dissolved in acetonitrile (200 ml), and N,N-diisopropylethylamine (19.5 ml) followed by 3,4-difluoronitrobenzene (2.25 ml) were added. The mixture was heated to reflux for 18 hours. Solvent was evaporated, and the residue chromatographed on silica using as eluant a gradient increasing in polarity from 0 to 20 4% methanol in dichloromethane. Relevant fractions were combined and evaporated to give a solid containing some N,N-diisopropylethylamine trifluoroacetate. The solid was purified by dissolving in ethyl acetate and washing well with water. Evaporation of the organic layer gave 3-fluoro-4-(4-ethyl-3-oxopiperazin-1-yl)nitrobenzene as a solid (3.44g).

25 MS (CI): 268 (MH⁺).

NMR (CDCl₃) δ: 1.21 (t, 3H); 3.50, 3.52 (q + t, 4H); 3.64 (t, 2H); 3.96 (s, 2H); 6.88 (t, 1H); 7.95 (dd, 1H); 8.02 (dd, 1H).

30 3-Fluoro-4-(4-ethyl-3-oxopiperazin-1-yl)nitrobenzene (3.4 g) was dissolved in ethyl acetate (200 ml) and the solution flushed with argon. Palladium (10% on carbon, 180 mg) was added, and the mixture hydrogenated under ambient pressure. After gas uptake had ceased,

the mixture was filtered through celite and solvent evaporated to give 5-amino-2-(4-ethyl-3-oxopiperazin-1-yl)fluorobenzene, which was used without further purification.

MS (Electrospray): 238 (MH⁺).

5

NMR (CDCl₃) δ: 1.17 (t, 3H); 3.25 (t, 2H); 3.41 (t, 2H); 3.48 (q, 2H); 3.61 (br s, 2H); 3.66 (s, 2H); 6.38 (dd, 1H); 6.42 (dd, 1H); 6.77 (t, 1H).

5-Amino-2-(4-ethyl-3-oxopiperazin-1-yl)fluorobenzene (2.95 g) was dissolved in dry dichloromethane (50 ml) under argon. Pyridine (1.26 ml) was added, and the mixture cooled to -20°C. Benzyl chloroformate (1.95 ml) was added, and the mixture stirred for 10 minutes at -20°C, before allowing the temperature to rise to ambient over 1.5 hours. Solvents were evaporated, the residue dissolved in dichloromethane and washed with sodium bicarbonate solution. After drying (MgSO₄) and evaporation of solvent, the residue 15 was chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 4% methanol in dichloromethane. Relevant fractions were combined and evaporated to give 5-benzyloxycarbonylamino-2-(4-ethyl-3-oxopiperazin-1-yl)fluorobenzene (3.3g).

MS (Electrospray): 372 (MH⁺).

20

NMR (CDCl₃) δ: 1.18 (t, 3H); 3.33 (t, 2H); 3.45 (t, 2H); 3.50 (q, 2H); 3.72 (s, 2H); 5.20 (s, 2H); 6.76 (br s, 1H); 6.82 (t, 1H); 6.96 (dd, 1H); 7.40 (m, 6H).

5-Benzylloxycarbonylamino-2-(4-ethyl-3-oxopiperazin-1-yl)fluorobenzene (3.25 g) was dissolved in dry THF (100 ml) under argon. The solution was cooled to -78°C, and treated with a solution of *n*-butyllithium (1.6 M in hexane, 6.02 ml), keeping the temperature below -60°C. 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone (DMPU, 10 ml) was added to the resulting mixture to facilitate stirring, and (R)-glycidylbutyrate (1.29 ml) added. Stirring was continued at -78°C for 30 minutes, before allowing the temperature to rise to ambient 30 over 16 hours. Sodium bicarbonate solution (50 ml) was added, followed by sufficient ethyl acetate to form two layers. The organic layer was separated, washed twice with water, dried (MgSO₄) and evaporated. The residue was chromatographed on silica, using as eluant a

gradient increasing in polarity from 0 to 6% methanol in dichloromethane. Relevant fractions were combined and evaporated to give (5R)-3-(3-fluoro-4-{4-ethyl-3-oxopiperazin-1-yl}phenyl)-5-hydroxymethyloxazolidin-2-one (990mg).

5 MS (Electrospray): 338 (MH⁺).

NMR (DMSO-D₆) δ: 1.08 (t, 3H); 3.28-3.41 (overlapping m, 6H); 3.59 (s + ddd, 3H); 3.66 (ddd, 1H); 3.80 (dd, 1H); 4.05 (t, 1H); 4.67 (m, 1H); 5.16 (t, 1H); 7.05 (t, 1H); 7.22 (dd, 1H); 7.55 (dd, 1H).

10

(5R)-3-(3-Fluoro-4-{4-ethyl-3-oxopiperazin-1-yl}phenyl)-5-hydroxymethyloxazolidin-2-one (830 mg) was dissolved in pyridine (20 ml), and cooled to 0°C. Triethylamine (0.41 ml) and methanesulfonyl chloride (0.21 ml) were added, and stirring continued at ambient temperature for 2 hours. Solvent was evaporated and the residue dissolved in ethyl acetate.

15 The resulting solution was washed with water, dried (MgSO₄), and evaporated to give (5R)-3-(3-fluoro-4-{4-ethyl-3-oxopiperazin-1-yl}phenyl)-5-(methanesulfonyloxyethyl)-oxazolidin-2-one (1.0g) which was used without further purification.

MS (Electrospray): 416 (MH⁺).

20

NMR (CDCl₃) δ: 1.20 (t 3H); 3.11 (s, 3H); 3.30-3.55 (m, 6H); 3.78 (s, 2H); 3.94 (dd, 1H); 4.14 (t, 1H); 4.46 (dq, 2H); 4.93 (m, 1H); 6.92 (t, 1H); 7.11 (dd, 1H); 7.49 (dd, 1H).

25 (5R)-3-(3-Fluoro-4-{4-ethyl-3-oxopiperazin-1-yl}phenyl)-5-(methanesulfonyloxyethyl)-oxazolidin-2-one (950 mg) was dissolved in dry DMF (30 ml) and sodium azide (893 mg) was added. The mixture was heated at 80°C for 5 hours, and then evaporated to dryness.

The residue was dissolved in ethyl acetate and the resulting solution washed with water and dried (MgSO₄). The crude product so obtained was chromatographed on silica, using as

30 eluant a gradient increasing in polarity from 0 to 6% methanol in dichloromethane.

Relevant fractions were combined and evaporated to give (5R)-5-azidomethyl-3-(3-fluoro-4-{4-ethyl-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one (777mg).

MS (Electrospray): 363 (MH⁺).

NMR (CDCl₃) δ: 1.20 (t, 3H); 3.38 (m, 2H); 3.45 (m, 2H); 3.50 (q, 2H); 3.58 (dd, 1H);
5 3.71 (dd, 1H); 3.78 (s, 2H); 3.83 (dd, 1H); 4.06 (t, 1H); 4.79 (m, 1H); 6.91 (t, 1H); 7.11
(dm, 1H); 7.52 (dd, 1H).

Example 3

(5R)-5-Azidomethyl-3-(3-fluoro-4-{4-(2-methoxyethyl)-3-oxopiperazin-1-
10 yl}phenyl)oxazolidin-2-one (750mg) was dissolved in ethyl acetate (15 ml), and the solution
purged with argon. Palladium (10% on carbon, 150mg) was added, followed by acetic
anhydride (0.36 ml) and the mixture stirred at ambient temperature under hydrogen confined
in a balloon for 2 hours. The mixture was filtered through celite, evaporated to dryness, and
chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 5%
15 methanol in dichloromethane. Relevant fractions were combined and evaporated, to give N-
(5S)-[3-(3-fluoro-4-{4-(2-methoxyethyl)-3-oxopiperazin-1-yl}phenyl)-2-oxooxazolidin-5-
yilmethyl]acetamide (228mg).

MS (Electrospray): 409 (MH⁺).

20

NMR (CDCl₃) δ: 2.03 (s, 3H); 3.35 (s + t, 5H); 3.63 (s + overlapping m, 8H); 3.77 (s +
overlapping m, 3H); 4.03 (t, 1H); 4.77 (m, 1H); 6.14 (br.t, 1H); 6.90 (t, 1H); 7.08 (dm,
1H); 7.47 (dd, 1H).

25 The (5R)-5-azidomethyl-3-(3-fluoro-4-{4-(2-methoxyethyl)-3-oxopiperazin-1-
yl}phenyl)oxazolidin-2-one used as starting material was prepared as follows :-

1-*tert*-Butoxycarbonyl-3-oxopiperazine (7.5g) was dissolved in dry DMF (250 ml) and
potassium *tert*-butoxide (8.4g) was added. The mixture was stirred at ambient temperature
30 for 30 minutes, then 1-bromo-2-methoxyethane (3.9 ml) added, and stirring continued at the
same temperature for 24 hours. A further equal portion of 1-bromo-2-methoxyethane was
added and stirring continued for 24 hours. Solvent was evaporated, and the residue

partitioned between ethyl acetate and water. The organic layer was washed with water and evaporated to give the 1-*tert*-butoxycarbonyl-4-(2-methoxyethyl)-3-oxopiperazine (6.7g) which was used without further purification.

5 MS (Electrospray): 259 (MH⁺).

NMR (CDCl₃) δ: 1.45 (s, 9H); 3.36 (s, 3H); 3.48 (t, 2H); 3.65 (m, 4H); 3.65 (t, 2H); 4.10 (s, 2H).

10 1-*tert*-Butoxycarbonyl-4-(2-methoxyethyl)-3-oxopiperazine (6.6g) was dissolved in dichloromethane (100 ml), the resulting solution cooled in an ice-bath, and trifluoroacetic acid (145 ml) added. The mixture was stirred at the same temperature for 2 hours. Solvent was evaporated to yield 1-(2-methoxyethyl)-2-oxopiperazine product as a salt with 4 moles of trifluoroacetic acid.

15

MS (CI): 159 (MH⁺).

NMR (DMSO-D₆ + CD₃CO₂H) δ: 3.30 (s, 3H); 3.43 (t, 2H); 3.54 (m, 4H); 3.64 (t, 2H); 3.78 (s, 2H).

20

1-(2-Methoxyethyl)-2-oxopiperazine (4TFA salt, 13.5g) was dissolved in acetonitrile (200 ml), and *N,N*-diisopropylethylamine (22.6 ml) followed by 3,4-difluoronitrobenzene (2.2 ml) were added. The mixture was heated to reflux for 18 hours. Solvent was evaporated, and the residue chromatographed on silica, using as eluant a gradient increasing in polarity 25 from 0 to 4% methanol in dichloromethane. Relevant fractions were combined and evaporated to give a solid containing some *N,N*-diisopropylethylamine trifluoroacetate. The solid was purified by dissolving in ethyl acetate and washing well with water. Evaporation of the organic layer gave 3-fluoro-4-(4-{2-methoxyethyl}-3-oxopiperazin-1-yl)nitrobenzene as a solid (4.07g).

30

MS (CI): 298 (MH⁺).

NMR (CDCl₃) δ: 3.31 (s, 3H); 3.63 (m, 6H); 4.00 (s, 2H); 6.89 (t, 1H); 7.95 (dd, 1H); 8.02 (dm, 1H).

3-Fluoro-4-(4-{2-methoxyethyl}-3-oxopiperazin-1-yl)nitrobenzene (4g) was dissolved in a mixture of ethyl acetate (200 ml) and DMF (5 ml), and the solution flushed with argon. Palladium (10% on carbon, 200mg) was added, and the mixture hydrogenated under ambient pressure. After gas uptake had ceased, the mixture was filtered through celite and solvent was evaporated to give 5-amino-2-(4-{2-methoxyethyl}-3-oxopiperazin-1-yl)fluorobenzene which was used without further purification.

10

MS (Electrospray): 268 (MH⁺).

NMR (CDCl₃) δ: 3.25 (t, 2H); 3.36 (s, 3H); 3.55 (t, 2H); 3.61 (s, 4H); 3.64 (br s, 2H); 3.70 (s, 2H); 6.40 (dd, 1H); 6.44 (dd, 1H); 6.77 (t, 1H).

15

5-Amino-2-(4-{2-methoxyethyl}-3-oxopiperazin-1-yl)fluorobenzene (3.5g) was dissolved in dry dichloromethane (50 ml) under argon. Pyridine (1.33 ml) was added, and the mixture cooled to -20°C. Benzyl chloroformate (2.06 ml) was added, and the mixture stirred for 10 minutes at -20°C, before allowing the temperature to rise to ambient over 1.5 hours.

20 Solvents were evaporated, the residue dissolved in dichloromethane and washed with sodium bicarbonate solution. After drying (MgSO₄) and evaporation of solvent, the residue was chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 4% methanol in dichloromethane. Relevant fractions were combined and evaporated to give 5-benzyloxycarbonylamino-2-(4-{2-methoxyethyl}-3-oxopiperazin-1-yl)fluorobenzene 25 (3.28g).

MS (Electrospray): 402 (MH⁺).

NMR (CDCl₃) δ: 3.32 (t, 2H); 3.34 (s, 3H); 3.56 (t, 2H); 3.62 (s, 4H); 3.75 (s, 2H); 5.19 (s, 2H); 6.82 (t, 1H); 6.84 (s, 1H); 6.97 (dd, 1H); 7.35 (m, 6H).

5-Benzylloxycarbonylamino-2-(4-{2-methoxyethyl}-3-oxopiperazin-1-yl)fluorobenzene (3.2g) was dissolved in dry THF (100 ml) under argon, cooled to -78°C, and treated with a solution of *n*-butyllithium (1.6 M in hexane, 5.5 ml), keeping the temperature below -60°C.

1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidone (DMPU, 10 ml) was added to the 5 resulting

mixture to facilitate stirring and (R)-glycidylbutyrate (0.93 ml) was added. The mixture was stirred at -78°C for 30 minutes, before allowing the temperature to rise to ambient over 16 hours. Sodium bicarbonate solution (50 ml) was added, and the whole evaporated to dryness. Organic materials were dissolved from the residue using dichloromethane, and 10 purified by chromatography on silica using as eluant a gradient increasing in polarity from 0 to 10% methanol in dichloromethane. Relevant fractions were combined and evaporated to give (5R)-3-(3-fluoro-4-{4-(2-methoxyethyl)-3-oxopiperazin-1-yl}phenyl)-5-hydroxy-methyloxazolidin-2-one (1.14g).

15 MS (Electrospray): 368 (MH⁺).

NMR (DMSO-D6) δ: 3.27 (s + m, 5H); 3.50 (t, 2H); 3.53 (m, 4H); 3.60 (m, 1H); 3.66 (s, 2H); 3.71 (m, 1H); 3.83 (dd, 1H); 4.08 (t, 1H); 4.71 (m, 1H); 5.20 (t, 1H); 7.09 (t, 1H); 7.24 (dd, 1H); 7.57 (dd, 1H).

20

(5R)-3-(3-Fluoro-4-{4-(2-methoxyethyl)-3-oxopiperazin-1-yl}phenyl)-5-hydroxymethyl-oxazolidin-2-one (1.0g) was dissolved in pyridine (25 ml), and cooled to 0°C.

Triethylamine (0.46 ml) and methanesulfonyl chloride (0.23 ml) were added, and stirring continued at ambient temperature for 2 hours. Solvent was evaporated and the residue

25 dissolved in ethyl acetate, washed with water, dried ($MgSO_4$), and evaporated to give (5R)-3-(3-fluoro-4-{4-(2-methoxyethyl)-3-oxopiperazin-1-yl}phenyl)-5-(methanesulfonyl-oxymethyl)oxazolidin-2-one (1.01g) which was used without further purification.

MS (Electrospray): 446 (MH⁺).

30

NMR (CDCl₃) δ: 3.11 (s, 3H); 3.36 (s, 3H); 3.37 (t, 2H); 3.58 (t, 2H); 3.63 (m, 4H); 3.80 (s, 2H); 3.93 (dd, 1H); 4.13 (t, 1H); 4.43 (dd, 1H); 4.50 (dd, 1H); 4.92 (m, 1H); 6.92 (t, 1H); 7.11 (dm, 1H); 7.48 (dd, 1H).

5 (5R)-3-(3-Fluoro-4-{4-(2-methoxyethyl)-3-oxopiperazin-1-yl}phenyl)-5-(methanesulfonyl-oxymethyl)oxazolidin-2-one (990mg) was dissolved in dry DMF (30 ml), sodium azide (868mg) was added, and the mixture heated at 80°C for 4 hours. The mixture was evaporated to dryness, and the residue dissolved in ethyl acetate and washed with three portions of water. The aqueous layer was back-extracted with two portions of ethyl acetate, 10 and the combined organic extracts dried over MgSO₄. Evaporation gave (5R)-5-azidomethyl-3-(3-fluoro-4-{4-(2-methoxyethyl)-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one (770mg) which was used without further purification.

MS (Electrospray): 393 (MH⁺).

15

NMR (CDCl₃) δ: 3.36 (s, 3H); 3.37 (t, 2H); 3.62 (overlapping m, 7H); 3.71 (dd, 1H); 3.78 (s, 2H); 3.83 (dd, 1H); 4.06 (t, 1H); 4.78 (m, 1H); 6.91 (t, 1H); 7.12 (dm, 1H); 7.49 (dd, 1H).

20 Example 4

(5R)-5-Azidomethyl-3-(3-fluoro-4-{4-(2-fluoroethyl)-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one (360mg) was dissolved in dry DMF (20ml), and the solution purged with argon. Palladium (10% on carbon, 72mg) was added, followed by acetic anhydride (0.17 ml) and the mixture stirred at ambient temperature under hydrogen confined 25 in a balloon for 3 hours. The mixture was filtered through celite, evaporated to dryness, and partitioned between ethyl acetate and water. The organic extract was washed with brine, dried (MgSO₄), and evaporated. The residue was chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 2.5% methanol in dichloromethane. Relevant fractions were combined and evaporated, to give N-(5S)-[3-(3-fluoro-4-{4-(2-30 fluoroethyl)-3-oxopiperazin-1-yl}phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide (166mg).

MS (Electrospray): 397 (MH⁺).

NMR (CDCl₃) δ: 2.02 (s, 3H); 3.38 (t, 2H); 3.61 (t + overlapping m, 3H); 3.70 (overlapping m, 3H); 3.81 (s + overlapping m, 3H); 4.03 (t, 1H); 4.58 (t, 1H); 4.75 (t, 1H); 4.80 (m, 1H); 6.19 (br t, 1H); 6.91 (t, 1H); 7.09 (dm, 1H); 7.51 (dd, 1H).

5

The (5R)-5-azidomethyl-3-(3-fluoro-4-{4-(2-fluoroethyl)-3-oxopiperazin-1-yl}phenyl)oxazolidin-2-one used as starting material was prepared as follows :-

1-*tert*-Butoxycarbonyl-3-oxopiperazine (21.6g) was dissolved in dry DMF (500 ml) and 10 potassium *tert*-butoxide (24.2g) was added. The mixture was stirred at ambient temperature for 30 minutes, then 1-(4-methylphenylsulfonyloxy)-2-fluoroethane (see J.Med.Chem. (1980), 23(9), 985-90 for outline of synthesis, 25.9g) added, and stirring continued at the same temperature for 24 hours. Solvent was evaporated, and the residue partitioned between ethyl acetate and water. The organic layer was washed with water and evaporated. 15 The residue was dissolved in isopropanol and diluted with iso-hexane, precipitating unchanged piperazinone starting material, which was removed by filtration. The solution was chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 50% isopropanol in iso-hexane. Relevant fractions were combined and evaporated to give 1-*tert*-butoxycarbonyl-4-(2-fluoroethyl)-3-oxopiperazine (6.74g).

20

MS (CI): 247 (MH⁺).

NMR (CDCl₃) δ: 1.49 (s, 9H); 3.50 (t, 2H); 3.66 (overlapping m, 3H); 3.77 (t, 1H); 4.11 (s, 2H); 4.53 (t, 1H); 4.72 (t, 1H).

25

1-*t*-Butoxycarbonyl-4-(2-fluoroethyl)-3-oxopiperazine (6.65g) was dissolved in dichloromethane (500 ml), cooled in an ice-bath, and trifluoroacetic acid (150 ml) added. The mixture was stirred at the same temperature for 2 hours. Solvent was evaporated to yield crude product, which was dissolved in the minimum volume of ethyl acetate. Slow 30 addition of diethyl ether caused precipitation of 1-(2-fluoroethyl)-2-oxopiperazine product as the mono trifluoroacetic acid salt (6.19g).

MS (CI): 147 (MH^+).

NMR (DMSO-D₆ + CD₃CO₂H) δ: 3.44 (t, 2H); 3.63 (t overlapping m, 3H); 3.76 (t, 1H); 3.81 (s, 2H); 4.50 (t, 1H); 4.69 (t, 1H).

5

1-(2-Fluoroethyl)-2-oxopiperazine trifluoroacetate (6.1g) was dissolved in acetonitrile (100 ml). N,N-Diisopropylethylamine (13 ml) was added to the mixture, followed by 3,4-difluoronitrobenzene (3.39g), and the mixture heated to reflux for 18 hours. Solvent was evaporated, and the residue chromatographed on silica, using as eluant a gradient increasing 10 in polarity from 0 to 4% methanol in dichloromethane. Relevant fractions were combined and evaporated to give 3-fluoro-4-(4-{2-fluoroethyl}-3-oxopiperazin-1-yl)nitrobenzene product as a solid (4.4g).

MS (Electrospray): 286 (MH^+).

15

NMR (CDCl₃) δ: 3.67 (s, 4H); 3.72 (t, 1H); 3.83 (t, 1H); 4.02 (s, 2H); 4.58 (t, 1H); 4.76 (t, 1H); 6.91 (t, 1H); 7.96 (dd, 1H); 8.02 (dm, 1H).

3-Fluoro-4-(4-{2-fluoroethyl}-3-oxopiperazin-1-yl)nitrobenzene (4.35g) was dissolved in a 20 mixture of ethyl acetate (250 ml) and DMF (5 ml), and the solution flushed with argon. Palladium (10% on carbon, 200mg) was added, and the mixture hydrogenated under ambient pressure. After gas uptake had ceased, the mixture was filtered through celite and solvent evaporated. The residue was taken up in ethyl acetate, washed twice with water, dried (MgSO₄), and evaporated, to give 5-amino-2-(4-{2-fluoroethyl}-3-oxopiperazin-1-yl)fluorobenzene product, which was used without further purification.

MS (Electrospray): 256 (MH^+).

NMR (CDCl₃) δ: 3.28 (t, 2H); 3.58 (t, 2H); 3.61 (br s, 2H); 3.68 (t, 1H); 3.72 (s, 2H); 3.80 (t, 1H); 4.56 (t, 1H); 4.75 (t, 1H); 6.40 (dd, 1H); 6.44 (dd, 1H); 6.78 (t, 1H).

5-Amino-2-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)fluorobenzene (2.6g) was dissolved in dry dichloromethane (50 ml) under argon. Pyridine (1.03 ml) was added, and the mixture cooled to -20°C. Benzyl chloroformate (1.6 ml) was added, and the mixture stirred for 10 minutes at -20°C, before allowing the temperature to rise to ambient over 1.5 hours.

5 Solvents were evaporated, the residue dissolved in dichloromethane and washed with sodium bicarbonate solution. After drying ($MgSO_4$) and evaporation of solvent, the residue was chromatographed on silica, using as eluant a gradient increasing in polarity from 0 to 5% methanol in dichloromethane. Relevant fractions were combined and evaporated to give 5-benzyloxycarbonylamino-2-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)fluorobenzene 10 (3.43g).

MS (Electrospray): 390 (MH^+).

NMR ($CDCl_3$) δ : 3.35 (t, 2H); 3.58 (t, 2H); 3.67 (t, 1H); 3.76 (s, 2H); 3.78 (t, 1H); 4.55 15 (t, 1H); 4.75 (t, 1H); 5.20 (s, 2H); 6.71 (br s, 1H); 6.85 (t, 1H); 6.99 (dd, 1H); 7.37 (m, 6H).

A solution of lithium *tert*-butoxide was prepared by addition of *n*-butyllithium (1.6 M in hexane, 2.9 ml) to a stirred solution of *tert*-butanol (0.43g) in anhydrous THF (10 ml) at 20 -10°C under argon. After cooling to -70°C, a solution of 5-benzyloxycarbonylamino-2-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)fluorobenzene (1.5g) in dry THF (15 ml) was added. After 10 minutes, (R)-glycidylbutyrate (0.67g) in dry THF (15 ml) was added to the resulting mixture, and stirring continued at -70°C for 15 minutes, before allowing the temperature to rise to ambient over 16 hours. Methanol (10 ml) was added, followed by 25 saturated sodium bicarbonate solution (20 ml) and water (10 ml). The organics were extracted into ethyl acetate (3 x 25 ml), washed with brine and dried ($MgSO_4$). Solvent was evaporated and the residue purified by chromatography on silica, using as eluant a gradient increasing in polarity from 0 to 3% methanol in dichloromethane. Relevant fractions were combined and evaporated to give (5*R*)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl)-5-hydroxymethyloxazolidin-2-one (1.07g).

MS (Electrospray): 356 (MH^+).

NMR (DMSO-D₆) δ: 3.32 (t, 2H); 3.50 (t, 2H); 3.66, 3.55-3.70 (s overlapping m, 5H); 3.63 (t, 1H); 3.78 (dd, 1H); 4.05 (t, 1H); 4.49 (t, 1H); 4.68 (t + m, 2H); 5.17 (t, 1H); 7.07 (t, 1H); 7.22 (dd, 1H); 7.55 (dd, 1H).

5

(5R)-3-(3-Fluoro-4-{4-(2-fluoroethyl)-3-oxopiperazin-1-yl}phenyl)-5-hydroxymethyl-oxazolidin-2-one (0.8g) was dissolved in pyridine (15 ml), and the mixture cooled to 0°C. Triethylamine (0.38 ml) and methanesulfonyl chloride (0.19 ml) were added to the mixture, and stirring continued at ambient temperature for 2 hours. Solvent was evaporated and the residue dissolved in dichloromethane, washed with water, brine, dried (MgSO₄), and evaporated. The resulting residue was triturated with diethyl ether to give (5R)-3-(3-fluoro-4-{4-(2-fluoroethyl)-3-oxopiperazin-1-yl}phenyl)-5-(methanesulfonyloxymethyl)-oxazolidin-2-one (0.76g) which was used without further purification.

15 MS (Electrospray): 432 (MH⁺).

NMR (CDCl₃) δ: 3.12 (s, 3H); 3.41 (t, 2H); 3.62 (t, 2H); 3.71 (t, 1H); 3.79 (t, 1H); 3.81 (s, 2H); 3.94 (dd, 1H); 4.15 (t, 1H); 4.43 (dd, 1H); 4.51 (dd, 1H); 4.59 (t, 1H); 4.75 (t, 1H); 4.95 (m, 1H); 6.93 (t, 1H); 7.11 (dm, 1H); 7.50 (dd, 1H).

20

(5R)-3-(3-Fluoro-4-{4-(2-fluoroethyl)-3-oxopiperazin-1-yl}phenyl)-5-(methanesulfonyloxymethyl)oxazolidin-2-one (719mg) was dissolved in dry DMF (15 ml), and sodium azide (647mg) added to the mixture. The mixture was heated at 80°C for 6 hours, and then evaporated to dryness. The resulting residue was dissolved in ethyl acetate, washed twice with water, and dried (MgSO₄). Evaporation gave (5R)-5-azidomethyl-3-(3-fluoro-4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl)oxazolidin-2-one (413mg) which was used without further purification.

25 MS (Electrospray): 381 (MH⁺).

30

NMR (CDCl₃) δ: 3.39 (t, 2H); 3.61 (t overlapping m, 3H); 3.75 (m, 2H); 3.80 (s overlapping m, 3H); 3.83 (dd, 1H); 4.06 (t, 1H); 4.58 (t, 1H); 4.74 (t, 1H); 4.79 (m, 1H); 6.92 (t, 1H); 7.13 (dm, 1H); 7.51 (dd, 1H).

5 Example 5

The following illustrate representative pharmaceutical dosage forms containing the compound of formula I, or a pharmaceutically-acceptable salt thereof (hereafter compound X), for therapeutic or prophylactic use in humans:

10 (a)	Tablet I	mg/tablet
	Compound X.....	100
	Lactose Ph.Eur.....	179
	Croscarmellose sodium.....	12
	Polyvinylpyrrolidone.....	6
15	Magnesium stearate.....	3
(b)	Tablet II	mg/tablet
	Compound X.....	50
	Lactose Ph.Eur.....	229
20	Croscarmellose sodium.....	12
	Polyvinylpyrrolidone.....	6
	Magnesium stearate.....	3
(c)	Tablet III	mg/tablet
25	Compound X.....	1
	Lactose Ph.Eur.....	92
	Croscarmellose sodium.....	4
	Polyvinylpyrrolidone.....	2
	Magnesium stearate.....	1

(d)	<u>Capsule</u>	<u>mg/capsule</u>
	Compound X.....	10
5	Lactose Ph.Eur	389
	Croscarmellose sodium.....	100
	Magnesium stearate	1

(e)	<u>Injection I</u>	<u>(50 mg/ml)</u>
10	Compound X	5.0% w/v
	Isotonic aqueous solution	to 100%


Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β cyclodextrin may be used to aid formulation.

15

Note

The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(e) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.

20

CLAIMS**1. A compound of the formula (I):**

5

(I)

wherein:

- R¹ is of the formula -NHC(=O)(1-4C)alkyl, -NHS(O)_n(1-4C)alkyl wherein n is 0, 1 or 2 or
10 R¹ is hydroxy;
- R² and R³ are independently hydrogen or fluoro;
- R⁴ is hydrogen, methyl, ethyl or oxo;
- R⁵ is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or of the formula R⁶(CH₂)_m
wherein either m is 1-4 and R⁶ is trifluoromethyl, difluoromethyl, fluoromethyl,
15 (1-4C)alkoxy, (1-4C)alkyl S(O)_p - wherein p is 0, 1 or 2, (1-6C)alkanoyloxy,
di-(N-(1-4C)alkyl)amino, N-((1-4C)alkyl)(1-4C)alkanoylamino, cyano, carboxy,
(1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, di-(N-(1-4C)alkyl)carbamoyl,
N-((1-4C)alkyl)(1-4C)alkanesulphonamido, N¹-((1-4C)alkyl)ureido,
N¹-((1-4C)alkyl)-N³-((1-4C)alkyl)ureido, N¹-((1-4C)alkyl)-di-(N³-(1-4C)alkyl)ureido,
20 or of the formula -OC(=O)NR⁷(R⁸) wherein R⁷ and R⁸ are independently hydrogen or
(1-4C)alkyl or of the formula -N(R⁹)SO₂NR⁷(R⁸) wherein R⁷ and R⁸ are as hereinabove
defined and R⁹ is (1-4C)alkyl;
or m is 2-4 and R⁶ is hydroxy, (1-4C)alkanoylamino, amino, (1-4C)alkylamino,
(1-4C)alkanesulphonamido, ureido, N³-((1-4C)alkyl)ureido, di-(N³-(1-4C)alkyl)ureido or of
25 the formula - NHSO₂NR⁷(R⁸) wherein R⁷ and R⁸ are as hereinabove defined;
and pharmaceutically-acceptable salts thereof.

2. A compound of the formula (I) as claimed in claim 1 wherein :R¹ is of the formula -NHC(=O)(1-4C)alkyl;R² and R³ is hydrogen and the other is fluoro;

R⁴ is hydrogen, methyl or oxo;

R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is trifluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.

3. A compound of the formula (I) as claimed in claim 1 wherein :

R¹ is acetamido;

R² and R³ is hydrogen and the other is fluoro;

R⁴ is hydrogen, methyl or oxo;

10 R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is trifluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2), (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.

4. A compound of the formula (I) as claimed in claim 1 wherein :

15 R¹ is acetamido;

R² and R³ is hydrogen and the other is fluoro;

R⁴ is hydrogen;

R⁵ is (1-6C)alkyl or of the formula R⁶(CH₂)_m- wherein either m is 1 or 2 and R⁶ is trifluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkylS(O)_p- (wherein p is 0, 1 or 2),

20 (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, or di-(N-(1-4C)alkyl)carbamoyl, or m is 2 or 3 and R⁶ is hydroxy or (1-4C)alkanoylamino.

5. A compound of the formula (I) as claimed in claim 1 wherein :

R¹ is acetamido;

R² and R³ is hydrogen and the other is fluoro;

25 R⁴ is hydrogen;

R⁵ is methyl, ethyl, 2, 2, 2-trifluoroethyl, 2-fluoroethyl, 2-methoxyethyl, methylthiomethyl, methoxycarbonylmethyl, carbamoylmethyl, di-(N-methyl)carbamoylmethyl, 2-hydroxyethyl or 2-(acetamido)ethyl.

6. A compound of the formula (I), or a pharmaceutically-acceptable salts thereof, as

30 claimed in claim 1 selected from :-

N-((5S)-3-(3-fluoro-4-(4-methyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-yl)-methyl)acetamide;

N-((5S)-3-(3-fluoro-4-(4-ethyl-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)-acetamide;

N-((5S)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide; and

5 N-((5S)-3-(3-fluoro-4-(4-(2-methoxyethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide.


7. A compound of the formula (I), or a pharmaceutically-acceptable salts thereof, as claimed in claim 1 being : -

N-((5S)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxopiperazin-1-yl)phenyl)-2-oxooxazolidin-5-ylmethyl)acetamide.

8. A process for the preparation of a compound of the formula (I) as claimed in claim 1 which comprises :-

(a) the deprotection a compound of the formula (II):

15




(II)

(b) the modification of a substituent in, or the introduction of a substituent into, another 20 compound of the formula (I);

(c) when R¹ is of the formula -NHS(O)_n(1-4C)alkyl, wherein n is 1 or 2, the oxidation of a compound of the formula (I) wherein n is 0 or, when n is 2 the oxidation of a compound of the formula (I) wherein n is 1;

(d) when R¹ is of the formula -NHC(=O)(1-4C)alkyl or -NHS(O)_n(1-4C)alkyl, the reaction 25 of a compound of the formula (III) with a compound of the formula (IV):




(III)




(IV)

(e) when R¹ is hydroxy, the reaction of a compound of the formula (V) with a compound 5 of the formula (VI):




(V)



(VI)

or

- (f) when R¹ is of the formula -NHC(=O)(1-4C)alkyl, the reaction of a compound of the formula (I) with an amide of the formula (VII) :



(VII)

wherein R², R³, R⁴ are as hereinabove defined; R¹⁰ is R¹ or protected R¹, R¹¹ is R⁵ or protected R⁵ (wherein R¹ and R⁵ are as hereinabove defined); R¹² is of the formula -C(=O)(1-4C)alkyl or --S(O)_n(1-4C)alkyl; R¹³ is (1-6C)alkyl or benzyl; R¹⁴ is (1-6C)alkyl and L¹ is a leaving group; and thereafter if necessary:

5 i) removing any protecting groups;

ii) forming a pharmaceutically-acceptable salt;

and when an optically active form of a compound of the formula (I) is required, it may be obtained by carrying out one of the above procedures using an optically active starting material or by resolution of a racemic form of the compound or intermediate using a standard procedure.

10 9. A pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, as claimed in any of claims 1 to 7 and a pharmaceutically-acceptable diluent or carrier.

10. The use of a compound of the formula (I) or a pharmaceutically-acceptable salt thereof, as claimed in any of claims 1 to 7 in the manufacture of a novel medicament for use

15 in the production of an antibacterial effect in a warm blooded animal, such as man.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/00169

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 6	C07D413/10 A61K31/42 A61K31/50	
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched - (classification system followed by classification symbols)		
IPC 6 C07D		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 23384 A (UPJOHN CO) 25 November 1993 see claims	1-5,9,10
X	WO 95 14684 A (UPJOHN CO) 1 June 1995 see claims	1-5,9,10
<input type="checkbox"/>	Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents :</p> <ul style="list-style-type: none"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*& document member of the same patent family</p>		
Date of the actual completion of the international search	Date of mailing of the international search report	
19 March 1997	26.03.97	
Name and mailing address of the ISA	Authorized officer	
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax. (+ 31-70) 340-3016	Henry, J	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/GB 97/00169

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9323384 A	25-11-93	AU 668733 B AU 4287793 A CN 1079964 A CZ 9402505 A EP 0640077 A FI 945246 A HU 72296 A HU 9500659 A JP 7506829 T NO 944237 A SK 133794 A US 5547950 A ZA 9302855 A	16-05-96 13-12-93 29-12-93 16-08-95 01-03-95 08-11-94 29-04-96 28-11-95 27-07-95 04-01-95 07-06-95 20-08-96 24-10-94
WO 9514684 A	01-06-95	AU 8010394 A CA 2174107 A CN 1135752 A EP 0730591 A ZA 9407885 A	13-06-95 01-06-95 13-11-96 11-09-96 09-04-96

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)